Page 29: "Wall street may be underestimating the heart-stent powerhouse. The company's next-generation stent, the Liberte, is already a hit in Europe, and the medical device maker has a slew of new products in the works for 2007." goes on for two pages.
MRK has stated goals of entering the med device arena... what better than BSX with steady cash flow of $1.5 Billion and a strong pipeline.... look for BSX to be gobbled in the next 12-18 months... min. price of $35.
They do have the cash. But how would it be a good fit? The argument might be that the powerful drug development capability closely combined with extensive device delivery/implantables will open up important new methods of treatment. Still, it is hard for me to imagine PFE going back to the cath lab this way.
As incredibly naive as you are, what's worse is your arrogance. Listen little man, you only think you know about this matter. You sound exactly like the IR people and PR people at Merck and PFE in the years before Vioxx was taken off the market. Your ignorance is palpable. You have no intellect or experience in the industry if you think clinical trials and follow ups tell the story. I don't really have the inclination to give you a mini-tutorial on the subject - just remember, your posts will look awfully foolish when they get re-posted at a later date. Keep the comments rolling.